Rezulin (troglitazone) is now approved for INITIAL therapy of type 2 diabetes

    Rezulin (troglitazone) is now approved for INITIAL therapy of type 2 diabetes...and for use with a sulfonylurea. Initially, it was approved only for patients poorly controlled on insulin.

    For initial therapy, Rezulin works about as well as metformin (Glucophage) or a sulfonylurea. It lowers blood sugar about 50 mg/dL...and reduces glycosylated hemoglobin (HbA1c) about 1.5%.

    Rezulin helps lower insulin resistance. It also seems to improve blood pressure and lipids.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote